Tumor necrosis factor (TNF)-alpha, a proinflammatory cytokine, has been implicated in the pathogenesis of AD. Objective: To investigate the use of a biologic TNF-alpha inhibitor, etanercept was ...

TNF Pharmaceuticals (TNFA) announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was ...

Rigel, of South San Francisco, California, is positioning R788 (tamatinib fodium), an inhibitor of Syk kinase, as a direct challenger to the tumor necrosis factor-alpha (TNF-α) inhibitor biologics.

55 11 3061 7457 Fax: +55 11 3081 7190 [email protected] Establishing that TNF-α plays an important role in the pathogenesis of several immune-mediated inflammatory diseases led to the development of ...

Isomyosamine targets excess pro-inflammatory TNF-alpha, a primary cause of sarcopenia. “Findings from the initial observational study will inform our forward move into multiple planned clinical ...